Immix Biopharma Stock Performance
| IMMX Stock | USD 9.70 -0.05 -0.51% |
Risk-Adjusted Performance
0High
11 · Balanced
Recent 90-day data places Immix Biopharma below 11% of comparable global equities and portfolios in return efficiency. The ranking helps frame whether return has been adequate relative to the risk absorbed. Immix Biopharma posted solid risk-adjusted performance recently, with return efficiency outpacing the broader market. Learn More
Actual Historical Performance (%)
One Day Return 2.2 | Five Day Return 1.99 | Year To Date Return 86.42 | Ten Year Return 165.67 | All Time Return 165.67 |
1 | Immix Biopharma to Participate in Upcoming Investor Conferences | 03/03/2026 |
2 | This Valaris Analyst Is No Longer Bullish Here Are Top 5 Downgrades For Monday | 03/09/2026 |
3 | Immix Biopharma Hits New 12-Month High Heres Why | 03/16/2026 |
4 | Immix stock wins Morgan Stanley bullish view - Seeking Alpha | 03/25/2026 |
5 | Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones | 03/30/2026 |
6 | Acquisition by Buchan Jane of 1127 shares of Immix Biopharma subject to Rule 16 b-3 | 04/02/2026 |
7 | Immix Biopharma price target increased by 11.73 percent to 18.62 - MSN | 04/13/2026 |
8 | We Think Immix Biopharma Can Afford To Drive Business Growth | 05/05/2026 |
Performance Related Modules
Relative Risk vs. Return Landscape
If you had invested $ 673.00 in Immix Biopharma on February 10, 2026 and sold it today, you would have earned $ 303.00 , a return of 45.02% over 90 days. Immix Biopharma is currently generating a 0.7069% daily expected return and carries 5.01% risk (volatility on return distribution) over a 90-day horizon. In relative terms, Immix Biopharma exhibits above-average volatility, exceeding roughly 55% of comparable stocks, and IMMX has trailed 86% of traded instruments in return over the 90-day horizon. Expected Return |
| Risk |
Target Price Odds to finish over Current Price
Price behavior in Immix Biopharma Stock may occasionally drift away from historical averages, particularly during periods of elevated market sentiment or uncertainty. However, deviations from historical norms do not necessarily imply that prices will quickly reverse.
| Current Price | Horizon | Target Price | Odds moving above the current price in 90 days |
| 9.70 | 90 days | 9.70 | about 24.69 % |
A normal distribution analysis suggests that the odds of Immix Biopharma moving above the current price in 90 days from now are about 24.69 %. Recent return data has shown a distribution that skews above the current level over this window. (The chart shows where the base-case price path for Immix Biopharma Stock has been concentrating over 90 days). Wider tails indicate a broader spread of plausible outcomes for Immix Biopharma Stock.
Immix Biopharma Price Density |
| Price |
Predictive Modules for Immix Biopharma
The stock market offers a wide variety of forecasting techniques applicable to instruments like Immix Biopharma. While no single technique guarantees accuracy, combining multiple methods often improves prediction reliability.Mean reversion in Immix Biopharma's price occurs when temporary dislocations correct back toward its historical intrinsic value estimate. This tendency of Immix Biopharma's price to converge to an average value over time is called mean reversion.
Primary Risk Indicators
The stock market has gone through extended turbulence over the past two decades, and Immix Biopharma has not been immune. Sharp price drops and substantial rallies have shaped Immix Biopharma's value during this period.α | Alpha over Dow Jones | 0.84 | |
β | Beta against Dow Jones | 2.13 | |
σ | Overall volatility | 1.14 | |
Ir | Information ratio | 0.16 |
Investor Alerts and Insights
Setting up alerts on Immix Biopharma ensures that material changes in technical or fundamental conditions are not missed. Notifications for Immix Biopharma surface changes in technical patterns and fundamental metrics that could influence decisions.| Immix Biopharma is way too risky over 90 days horizon | |
| Immix Biopharma appears to be risky and price may revert if volatility continues | |
| Immix Biopharma has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was -$29.44 million with profit before overhead, payroll, taxes, and interest of . | |
| Immix Biopharma currently holds about $18.4 million in cash as of latest reporting with -$23.93 million of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.32. | |
| Immix Biopharma has a poor financial position based on the latest SEC disclosures | |
| Roughly 21.0% of IMMX shares are held by company insiders | |
| Latest headline from finance.yahoo.com: We Think Immix Biopharma Can Afford To Drive Business Growth |
Price Density Drivers
The price behavior of Immix Biopharma is influenced by tension between bullish and bearish positioning among market participants. The future price of Immix Biopharma Stock depends on both market expectations and ongoing dynamics among participants.
| Common Stock Shares Outstanding | 32.97 million | |
| Cash And Short Term Investments | 100.41 million |
Immix Biopharma Fundamentals Growth
Immix Biopharma's fundamentals serve as the primary lens through which investors evaluate Immix Biopharma Stock. Key drivers such as revenue growth, earnings trends, and margin expansion directly influence Immix Biopharma Stock valuation.
| Current Valuation | 441.51 M | |||
| Shares Outstanding | 54.41 M | |||
| Earnings Per Share | -0.92 X | |||
Performance Metrics & Calculation Methodology
Immix Biopharma risk-adjusted performance measures whether returns compensate for the volatility borne by holders. Higher risk-adjusted returns suggest that performance quality, not just magnitude, supports the result. Immix Biopharma shows ROE of -74.46%, ROA of -38.97% (TTM) vs -29.0% (last reported).
Immix Biopharma analytics rely on periodic company reporting and market reference feeds, with quality checks and normalization applied. Analyst inputs may be included when coverage is available. Return and risk statistics are calculated from historical price series.
Editorial review and methodology oversight provided by: Rifka Kats, Member of Macroaxis Editorial Board